The title for the world's first true non-invasive, continuous blood glucose monitor is widely claimed by Afon Technology for their device, Glucowear, which is designed to monitor blood sugar levels via the wrist without piercing the skin. Other emerging technologies like Liom Health and GlucoModicum are also developing competing needle-free wearable platforms.

Key Features of Glucowear

• No Needles: Uses patented radio frequency/microwave technology to read glucose levels without breaking the skin.
• Form Factor: Built to be worn on the inside of the wrist, integrated into a watch-like band.
  
• Real-Time Data: Streams continuous tracking metrics straight to a paired smart device.
• Pain-Free: Eliminates traditional finger pricking or sub-dermal filament insertion.
  

Current Status and Validation

• Clinical Trials: Initial safety and feasibility trials (such as those in Germany) have proved it can read glucose trends without skin penetration.
• Accuracy Milestones: Recent real-world data presentations show around 75% accuracy in distinguishing normal versus elevated ranges, with ongoing refinements targeting commercial medical-grade regulatory clearance.
• 
  

If you'd like, I can provide details on:

• How radio-frequency sensors measure glucose without blood contact
• Other companies working on non-invasive tech (like GlucoModicum or Liom)
• Regulatory timelines for market availability.

"A small Welsh company has successfully developed the world’s first non-invasive and wearable glucose sensor that can measure blood sugar levels without penetrating the skin, latest research proves," the European Commission says.

"Results of a clinical study to be published in the Journal of Diabetes Science and Technology has confirmed that Afon Technology’s innovative device in the guise of a watch can successfully read a person’s blood glucose levels without having to inject into the skin. During the trial conducted in Germany, the team of researchers ran multiple tests using the Afon device, which is set to transform the lives of those living with diabetes.

Afon Technology’s  CEO, Sabih Chaudhry said: “Our device will be a game-changer for those living with diabetes, as it provides a pain-free and convenient way to monitor their blood glucose levels.”

He added: “This innovation is a testament to the power of innovation and the incredible possibilities that arise when we push the boundaries of what is possible.”

"Afon Technology’s Glucowear™ device has achieved approximately 75 per cent overall accuracy in distinguishing between normal and elevated blood glucose levels during its first, real-world trial. The innovative device was worn by Sabih Chaudhry, CEO of Afon Technology, who tested it during his regular daily activities, with the sensor placed on his dominant writing hand.

"The attached graph shows Glucowear™ readings, highlighting both high and normal glucose ranges alongside corresponding FreeStyle Libre data. The Monmouthshire-based company is pioneering the world’s first non-invasive blood glucose monitor, which is tipped to transform diabetes care."

"Afon Technology Ltd is poised to revolutionise blood glucose monitoring, offering Glucowear as a continuous, pain-free and real-time solution for individuals with diabetes and those at risk. Glucowear addresses the critical challenges with the current monitoring landscape, empowering people with diabetes to better manage their condition" Afon Technology says.

"Afon is making significant progress as we enter clinical trials ahead of our anticipated launch in 2026. This is an exciting phase that brings us closer to delivering an innovative solution for the diabetes market. Glucowear will reinvent diabetes management from a medicalised “patient” centric positioning to one of freedom from the disease; be proactive and empowered and manage their condition with a fun, fashionable, lifestyle accessory."

"In December 2022, Afon Technology were awarded a €2.5m grant from the European Innovation Council. 'Afon were one of only six UK based winners to be awarded this prestigious prize funding from amongst thousands of applicants across Europe. This grant is designed to help individual start-ups and small companies to develop and scale up game changing innovations."